Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Key Points

• Wall Street Zen upgraded Regeneron Pharmaceuticals to “strong buy” from “buy.” Analysts overall rate the stock “Moderate Buy,” with 16 buy ratings, 10 holds and an average price target of $793.74.
• Regeneron reported strong quarterly results, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion; revenue increased 16.7% year over year.
• The company is expanding its pipeline through oncology and antibody-conjugate collaborations, but investors face risks from insider selling and a proposed securities class action tied to disclosures surrounding the failed fianlimab-Libtayo melanoma trial.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued on Saturday.

REGN has been the subject of a number of other research reports. Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. Benchmark upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a research note on Thursday, July 9th. Finally, BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research report on Monday, May 18th. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $793.74.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $803.48 on Friday. The business's 50 day simple moving average is $675.79 and its 200 day simple moving average is $714.34. Regeneron Pharmaceuticals has a one year low of $541.00 and a one year high of $821.11. The stock has a market capitalization of $82.73 billion, a PE ratio of 19.86, a PEG ratio of 1.37 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the business earned $12.81 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current year.

Insider Activity

In related news, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the sale, the director directly owned 603 shares of the company's stock, valued at $482,400. The trade was a 39.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock worth $1,090,030 in the last three months. Company insiders own 6.97% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of REGN. Orbimed Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $11,358,000. Lockheed Martin Investment Management Co. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $2,702,000. National Pension Service increased its position in shares of Regeneron Pharmaceuticals by 29.8% during the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company's stock valued at $278,636,000 after acquiring an additional 82,853 shares during the last quarter. AE Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 36.7% during the fourth quarter. AE Wealth Management LLC now owns 5,474 shares of the biopharmaceutical company's stock valued at $4,226,000 after acquiring an additional 1,470 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $10,472,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is expanding its oncology relationship with Biohaven through a clinical supply agreement to test Biohaven’s BHV-1530 alongside Regeneron’s Libtayo in patients with solid tumors. The combination could strengthen Regeneron’s oncology pipeline if clinical results are favorable. Biohaven-Regeneron Oncology Deal
• Positive Sentiment: Regeneron also entered a strategic research collaboration with Parabilis Medicines to develop antibody-Helicon conjugates. The agreement includes $125 million in upfront consideration and equity investment for Parabilis, with potential milestone payments of up to $2.2 billion plus royalties—highlighting Regeneron’s efforts to broaden its technology base and future pipeline. Parabilis Medicines-Regeneron Collaboration
• Neutral Sentiment: Coverage highlights Regeneron’s exposure to GLP-1-related growth opportunities beyond the leading weight-loss drug makers, although the article provides limited new company-specific financial information. GLP-1 Demand and Regeneron
• Neutral Sentiment: Director Kathryn Guarini sold $320,000 of REGN stock under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance, it is a limited indicator of management’s current outlook.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron concerning alleged disclosures about the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, and the continuing legal notices may keep investor attention focused on potential litigation costs, disclosure risks and weakness in the oncology program. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source